Cogstate PT receives Investment Bank Analyst Rating Update
March 8 (Reuters) - CogState Ltd CGS.AX : * COGSTATE LTD - BUSINESS UPDATE-CGS.AX * COGSTATE LTD - CLINICAL TRIALS SALES CONTRACTS EXECUTED IN 3Q21 TO DATE TOTAL US$10.7 MILLION
Feb 25 (Reuters) - CogState Ltd CGS.AX : * H1 NET LOSS AFTER TAX USD -400,000 VERSUS USD -2.7 MILLION LOSS YEAR AGO * H1 GROUP REVENUE INCREASED 59% ON PCP TO $13.9M
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Cogstate Limited, a neuroscience technology company, provides computerized cognitive tests and electronic clinical outcome assessment solutions. The company’s cognitive services include project management, data management, scientific consulting, statistical analysis, scales procurement, rater training, and monitoring solutions. It operates in Clinical Trials and Healthcare segments. The Clinical Trials segment provides technology and associated services that are used to quantify the effect of diseases and drugs, and devices or other interventions on human subjects participating in clinical trials primarily conducted by pharmaceutical and biotechnology companies. The Healthcare segment provides Cognigram, a system for regular and standardized testing to assist primary care physicians and/or hospitals in the early detection of cognitive decline. As of June 30, 2022, it had participated in approximately 1,800 academic research. Cogstate Limited was incorporated in 1999 and is based in Melbourne, Australia.
|Average||197.000 (+10133.77% Upside)|
|No. of Analysts||3|